A new survey finds that only 17 drugs are under active development for maternal health indications, which is less than 3% of the pipeline in cardiovascular health (660 drugs). The international agencies have forgotten pregnant women. Given the unacceptably high number of maternal and perinatal...

This paper attempts to identify the factors that determine the export competitiveness of firms in the Indian pharmaceutical industry. Our findings suggest that the competitiveness of firms depends not only on firm specific advantages but also on government fiscal incentives. Among the firm...

The paper analyzes the determinants of internationalisation, defined in terms of export intensity and overseas investments, of the IT firms in India. In particular, the paper examines the role of technology sourcing, both internal (in-house R&D) and external (technology imports), in determining...

Tomotaoes which are produced in Gujarat, north west India are small, so the growers were not organized enough to raise funds to sponsor research at public R&D institutions in the area. That task was therefore taken up. Boxes that protected the produce better on long journey and were affordable...

In this context, higher education as well as research and development (R&D) have long since ceased to be purely the domain of the developed Western economies. Numerous regions of the world, some in the emerging markets in particular – the often-cited BRIC countries – are catching...

The paper seeks to prove the point that the Indian OTC derivatives markets, unlike many other jurisdictions, are well regulated. Only contracts where one party to the contract is an RBI regulated entity are considered legally valid in India. A good reporting system and a post-trade clearing and...

There is a strong feeling among especially the West that India is becoming very innovative. The study will take the reader through the empirical evidence on whether this is indeed the case since the reform process of 1991. The actual innovative performance of India’s economy since...

Introducing patent rights in developing country markets might stimulate greater R and D investment targeting their specific health needs – areas long neglected. This paper examines this argument using statistical data and survey evidence. We identify a set of diseases where 99 per cent of...

The focus of this paper is India. In line with TRIPS India has introduced a product patent regime in pharmaceuticals from 1 January, 2005. WIll this lead increase in resources deveoted to R and D by Indian companies for the development of new drugs more suited to the needs of India and other...